Literature DB >> 8088063

Cyclosporin in Behçet's disease: results in 16 patients after 24 months of therapy.

M L Pacor1, D Biasi, C Lunardi, P Cortina, P Caramaschi, D Girelli, M Botto, G Urbani, G Lombardo, L M Bambara.   

Abstract

The aim of this study was to evaluate the usefulness of cyclosporin in Behçet's disease. Sixteen subjects (10 males and 6 females; mean age 25.2 years) affected by the complete type of Behçet's syndrome received 5 mg/kg/day of cyclosporin for 24 months. A marked improvement of the symptoms was observed after three months of therapy. Within 6 to 12 months of treatment 14 of the 16 patients obtained a complete clinical remission. Biochemical and immunological parameters were controlled periodically to evaluate the clinical response and the possible side-effects. Two patients dropped out of the study because of anaemia and renal dysfunction, which returned to normal when cyclosporin was withdrawn. Our results confirm the efficacy of cyclosporin in the treatment of Behçet's disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8088063     DOI: 10.1007/bf02249016

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  15 in total

1.  Treatment of Behcet's disease with chlorambucil.

Authors:  D Tricoulis
Journal:  Br J Ophthalmol       Date:  1976-01       Impact factor: 4.638

2.  Abnormalities of T-cell subsets in Behçet's syndrome.

Authors:  S D Lim; C R Haw; N I Kim; R M Fusaro
Journal:  Arch Dermatol       Date:  1983-04

3.  Damaged membrane fragments and immune complexes in the blood of patients with Behcet's syndrome.

Authors:  T Lehner; J D Almeida; R J Levinsky
Journal:  Clin Exp Immunol       Date:  1978-11       Impact factor: 4.330

4.  The high prevalence of HLA-B5 in Behçet's disease.

Authors:  H Yazici; G Akokan; B Yalçin; A Müftüoğlu
Journal:  Clin Exp Immunol       Date:  1977-11       Impact factor: 4.330

5.  The relationship of HLA-B and DR phenotypes to Behcet's syndrome, recurrent oral ulceration and the class of immune complexes.

Authors:  T Lehner; K I Welsh; J R Batchelor
Journal:  Immunology       Date:  1982-12       Impact factor: 7.397

6.  Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease.

Authors:  J D O'Duffy; D M Robertson; N P Goldstein
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

7.  Immunological aspects of Behçet's and Vogt-Koyanagi-Harada's diseases.

Authors:  S Ohno
Journal:  Trans Ophthalmol Soc U K       Date:  1981-09

8.  [Effects of azathioprine ("Imuran") in Behcet's disease. Preliminary therapeutic results].

Authors:  E Rosselet; Y Saudan; G Zenklusen
Journal:  Ophthalmologica       Date:  1968       Impact factor: 3.250

9.  Cyclosporin a. Inhibition of experimental autoimmune uveitis in Lewis rats.

Authors:  R B Nussenblatt; M M Rodrigues; W B Wacker; S J Cevario; M C Salinas-Carmona; I Gery
Journal:  J Clin Invest       Date:  1981-04       Impact factor: 14.808

10.  Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome.

Authors:  D BenEzra; E Cohen; T Chajek; G Friedman; S Pizanti; C de Courten; W Harris
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

View more
  5 in total

Review 1.  Immunosuppression in uveitis therapy.

Authors:  R N Van Gelder; H J Kaplan
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Development of an activity disease score in patients with uveitis (UVEDAI).

Authors:  Esperanza Pato; Mª Auxiliadora Martin-Martinez; Adela Castelló; Rosalía Méndez-Fernandez; Santiago Muñoz-Fernández; Miguel Cordero-Coma; Lucia Martinez-Costa; Elia Valls; Miguel Reyes; Félix Francisco; Mar Esteban; Alex Fonollosa; Fernando Sanchez-Alonso; Cruz Fernández-Espartero; Teresa Diaz-Valle; José Miguel Carrasco; Emma Beltran-Catalán; Marisa Hernández-Garfella; María Victoria Hernández; Laura Pelegrin; Ricardo Blanco; David Diaz-Valle
Journal:  Rheumatol Int       Date:  2016-11-04       Impact factor: 2.631

Review 3.  Update on the therapy of Behçet disease.

Authors:  Zeinab Saleh; Thurayya Arayssi
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

4.  Long-term therapy with low dose cyclosporin A in ocular Behçet's disease.

Authors:  Pinar Cakar Ozdal; Serap Ortaç; Ibrahim Taskintuna; Esin Firat
Journal:  Doc Ophthalmol       Date:  2002-11       Impact factor: 2.379

5.  Very low-dose cyclosporin treatment of steroid-resistant interstitial pneumonitis associated with Sjögren's syndrome.

Authors:  H Ogasawara; M Sekiya; A Murashima; T Hishikawa; Y Tokano; I Sekigawa; N Iida; H Hashimoto; S Hirose
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.